SAB Biotherapeutics, Inc. announced on March 10, 2026, additional Phase 1 data showing that in a trial with adults who have Type 1 Diabetes (n=6), 4 who received SAB-142 maintained C-peptide levels, indicating potential preservation of beta cell function, while 2 placebo participants did not. This event is deemed significant for investors as it highlights promising results of the ongoing clinical trial.